![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...
100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed...
92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen...
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0375 | 4.62107208872 | 0.8115 | 0.9172 | 0.8003 | 125491 | 0.85191077 | CS |
4 | -0.151 | -15.1 | 1 | 1.02 | 0.7605 | 279797 | 0.89383596 | CS |
12 | -0.151 | -15.1 | 1 | 1.74 | 0.7605 | 401196 | 1.16326481 | CS |
26 | -0.681 | -44.5098039216 | 1.53 | 1.74 | 0.7605 | 355358 | 1.15273682 | CS |
52 | -0.741 | -46.6037735849 | 1.59 | 2.48 | 0.65 | 364108 | 1.3181818 | CS |
156 | -9.151 | -91.51 | 10 | 10.319 | 0.65 | 584519 | 2.46491999 | CS |
260 | -9.151 | -91.51 | 10 | 10.319 | 0.65 | 584519 | 2.46491999 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions